Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers

被引：0

作者：

Atkins, Michael ^{[1
]}

Martini, Jean-Francois ^{[2
]}

Plimack, Elizabeth ^{[3
]}

McDermott, David ^{[4
]}

Puzanov, Igor ^{[5
]}

Fishman, Mayer ^{[6
]}

Cho, Daniel ^{[7
]}

Vaishampayan, Ulka ^{[8
]}

Rosbrook, Brad ^{[2
]}

Fernandez, Kathrine ^{[9
]}

Tarazi, Jamal ^{[2
]}

George, Saby ^{[5
]}

Choueiri, Toni ^{[10
]}

机构：

[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[2] Pfizer Global Prod Dev Oncol, San Diego, CA USA

[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[4] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[5] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] NYU, Langone Med Ctr, New York, NY USA

[8] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[9] Pfizer Global Prod Dev Oncol, Cambridge, MA USA

[10] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

CANCER RESEARCH | 2019年 / 79卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2019-CT093

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT093

引用

页数：2

共 50 条

[21] Efficacy outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
McGregor, Bradley Alexander
Geynisman, Daniel M.
Burotto, Mauricio
Porta, Camillo
Rodriguez, Cristina Suarez
Bourlon, Maria Teresa
Barata, Pedro C.
Gulati, Shuchi
Stwalley, Brian
Del Tejo, Viviana
Du, Ella X.
Wu, Aozhou
Chin, Andi
Betts, Keith A.
Huo, Stephen
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
Motzer, Robert J.
Porta, Camillo
Alekseev, Boris
Rha, Sun Young
Choueiri, Toni K.
Mendez-Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Goh, Jeffrey C.
Eto, Masatoshi
Wang, Jinyi
Pan, Janice
Asfaw, Alemseged Ayele
He, Cixin Steven
Mody, Kalgi
Cella, David
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[23] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Waddell, Tom
Gafanov, Rustem
Pouliot, Frederic
Nosov, Dmitry
Melichar, Bohuslav
Soulieres, Denis
Borchiellini, Delphine
Vynnychenko, Ihor
McDermott, Raymond S.
Azevedo, Sergio Jobim
Tamada, Satoshi
Kryzhanivska, Anna
Li, Chenxiang
Burgents, Joseph E.
Molife, L. Rhoda
Rini, Brian I.
Bedke, Jens
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Teh, Jiasian
Narasimhan, Vignesh
Schultz, Stephen
Sathianathen, Niranjan
Murphy, Declan G.
EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
[25] Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma Comment
Procopio, Giuseppe
Nichetti, Federico
Verzoni, Elena
LANCET ONCOLOGY, 2020, 21 (12): : 1538 - 1539
[26] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
Choueiri, Toni K.
Larkin, James M. G.
Oya, Mototsugu
Thistlethwaite, Fiona C.
Martignoni, Marcella
Nathan, Paul D.
Powles, Thomas
McDermott, David F.
Robbins, Paul B.
Chism, David D.
Cho, Daniel C.
Atkins, Michael B.
Gordon, Michael S.
Gupta, Sumati
Uemura, Hirotsugu
Tomita, Yoshihiko
Compagnoni, Anna
Di Pietro, Alessandra
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
Motzer, Robert J.
Penkov, Konstantin
Uemura, Hirotsugu
Campbell, Matthew T.
Kollmannsberger, Christian K.
Lee, Jae-Lyun
Venugopal, Balaji
Van Den Eertwegh, Alfonsus
Negrier, Sylvie
Gurney, Howard
Albiges, Laurence
Berger, Raanan
Haanen, John
Rini, Brian I.
Larkin, James
Schmidinger, Manuela
Sandner, Robin
Wang, Jing
Di Pietro, Alessandra
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[28] Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
Tannir, Nizar M.
Naing, Aung
Infante, Jeffrey R.
Papadopoulos, Kyriakos P.
Wong, Deborah J. L.
Korn, Michael
Aljumaily, Raid
Autio, Karen A.
Pant, Shubham
Bauer, Todd Michael
Drakaki, Alexandra
Daver, Naval Guastad
Hung, Annie
Van Vlasselaer, Peter
Leveque, Joseph
Oft, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
Ged, Yasser
Lee, Chung-Han
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
[30] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
Powles, Thomas
Plimack, Elizabeth R.
Stus, Viktor
Gafanov, Rustem Airatovich
Hawkins, Robert E.
Nosov, Dmitry
Pouliot, Frederic
Alekseev, Boris Yakovlevich
Soulieres, Denis
Melichar, Bohuslav
Vynnychenko, Ihor
Kryzhanivska, Anna
Bondarenko, Igor
Azevedo, Sergio Jobim
Borchiellini, Delphine
Shou, Qiong
Perini, Rodolfo F.
Chen, Mei
Atkins, Michael B.
Rini, Brian I.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

← 1 2 3 4 5 →